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Abstract 
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is almost 
exclusively effective in patients with activating EGFR mutations, and median time to 
progression in such patients is generally up to 12 months. Usually, treatment with EGFR-
TKI is terminated when disease progression is confirmed; however, acute exacerbation 
after the withdrawal of EGFR-TKI has been reported. In this paper, we report a case of a 
35-year-old patient whose disease rapidly progressed after discontinuation of gefitinib 
and then rapidly regressed after reintroduction of gefitinib. In addition, we summarize 
the cases of 3 other patients who could be safely treated with continued erlotinib in 
combination with pemetrexed after disease progression. Currently, the mechanism of 
acquired resistance is intensively investigated and a number of new agents, such as 
irreversible EGFR inhibitors or MET inhibitors, are under development; however, they are 
still unavailable in clinical setting. We believe that continuing EGFR-TKI treatment after 
disease progression should be an option in patients who previously responded to EGFR-
TKI under the present circumstances. 
 
Introduction 
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), such as 
gefitinib or erlotinib, has been approved for the treatment of non-small cell lung cancer 
(NSCLC) in many countries, and it is widely accepted that specific mutations in the ATP-
binding site of EGFR are strongly associated with the response to EGFR-TKI. Patients 
with such mutations greatly benefit from EGFR-TKI; however, median time to Case Rep Oncol 2011;4:470–474 
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progression is reportedly 7.7–13.3 months because of acquired resistance. Treatment with 
EGFR-TKI is generally terminated once disease progression is confirmed, although a 
previous report suggests acute exacerbation after withdrawal of EGFR-TKI. We report the 
case of a patient with NSCLC whose disease rapidly progressed after discontinuation of 
gefitinib and then restarted concurrently with cytotoxic chemotherapy. We also present 
the cases of 3 other patients who continued erlotinib after disease progression in 
combination with pemetrexed. 
Case Report 
A 35-year-old male former smoker, presenting with severe cough for the past several months, was 
referred to our hospital and was found to have miliary pulmonary nodules in both lungs. After 
admission, bronchoscopic examination was performed and histologic analysis revealed 
adenocarcinoma. He was diagnosed with lung adenocarcinoma with multiple lung, bone, and brain 
metastases. He complained of dyspnea and his Eastern Cooperative Oncology Group performance 
status was 3. His attending physician recommended gefitinib considering his poor performance status, 
and the treatment was initiated. His disease markedly improved without severe toxicity, and he was 
discharged from our hospital 1 month after admission (fig. 1a); however, 7 months later, he developed 
meningitis carcinomatosa and the multiple pulmonary metastases were exacerbated (fig. 1b). Gefitinib 
was terminated and whole brain irradiation was immediately started; however, miliary pulmonary 
metastases rapidly progressed during the following 3 weeks (fig. 1c), and gefitinib was restarted 
concurrently with gemcitabine and vinorelbine. Ten days later, the miliary pulmonary metastases 
rapidly improved (fig. 1d), and he continued to receive combination chemotherapy with gemcitabine, 
vinorelbine, and gefitinib; however, 4 months later, his disease progressed again and he died. The EGFR 
mutational status was unknown, while the patient was alive, but was later revealed to be the wild type; 
however, such a great benefit of gefitinib in wild-type patients is hard to imagine [1]. It seems possible 
to assume that the result was a false negative. The analyzed tissue was old and very small, which may 
have influenced the accuracy of the analysis. 
Discussion 
In 2007, Riely et al. [2] reported the results of their interesting study. Ten patients with 
NSCLC, who initially responded but later acquired resistance to EGFR-TKI, gefitinib or 
erlotinib, had 18-fluoro-2-deoxy-D-glucose-positron emission tomography/computed 
tomography (PET/CT) and computed tomography (CT) at baseline, 3 weeks after 
stopping EGFR-TKI, and 3 weeks after restarting EGFR-TKI. Three weeks after stopping 
EGFR-TKI, there was a median 18% increase in SUVmax and a 9% increase in tumor 
diameter, and 7 out of 10 patients showed worsening lung cancer symptoms; however, 3 
weeks after restarting the same EGFR-TKI, there was a median 4% decrease in SUVmax 
and 1% decrease in tumor diameter, and all 7 patients whose symptoms had worsened 
after stopping EGFR-TKI stabilized or had improved symptoms [2]. These results suggest 
that some tumor cells remain sensitive to EGFR-TKI after disease progression has been 
confirmed. A similar phenomenon has also been reported with imatinib for 
gastrointestinal stromal tumor [3]. 
To date, 4 patients have been receiving EGFR-TKI after disease progression in our 
hospital (table 1). All 4 patients had adenocarcinoma histology, and EGFR-active 
mutation was confirmed in 2 patients. Initial response to EGFR-TKI was partial response 
(PR) in 3 patients and stable disease (SD) of long duration in 1 patient. Case 3 had 
previously received gefitinib and achieved PR. Pemetrexed was chosen for add-on 
chemotherapy except for the present case, and there were 1 PR, 1 long SD, and 1 Case Rep Oncol 2011;4:470–474 
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progressive disease (PD). Both case 1 and case 3 are currently being treated with the same 
regimen. 
Collectively, it seems that some types of patients will clearly benefit from continuing 
EGFR-TKI beyond PD; however, it is needless to say that a randomized trial comparing 
chemotherapy with or without continuation of EGFR-TKI at the time of acquired 
resistance is crucial for confirmation. 
When combining EGFR-TKI and chemotherapy, the best regimen for the EGFR-TKI 
partner with regard to both safety and efficacy is still unknown. Although previous large 
phase III studies did not show increased toxicity with the combination of carboplatin + 
paclitaxel or cisplatin + gemcitabine with EGFR-TKIs [4–7], multiple reports do not 
support the concurrent administration of vinorelbine and gefitinib because of severe 
toxicity [8, 9]. In a recent study, on the other hand, the combination of erlotinib and 
pemetrexed was reported to be feasible and well tolerated [10]. 
Currently, a number of new agents, such as irreversible EGFR inhibitors or MET 
inhibitors, are under development to overcome acquired resistance to EGFR-TKI [11]; 
however, they are still unavailable in clinical setting. Under the present circumstances, 
continuing EGFR-TKI after disease progression should be an option in patients who 
previously responded to EGFR-TKI. 
Disclosure Statement 
No author has a financial relationship with a commercial entity that has an interest in the topic of 
this paper. 
 
 
 
Table 1. Summary of patients who received EGFR-TKI beyond PD in combination with a cytotoxic 
agent 
Case Age/sex  Histology  EGFR   
mutation 
EGFR-TKI/response Response 
duration 
Add-on/response  <Response 
<duration 
<(post  
   add-on) 
1 62/male  adenocarcinoma  L858R  erlotinib (2nd-line)/PR  251 days  pemetrexed/PR  >176 days 
2  73/male  adenocarcinoma  L858R  erlotinib (2nd-line)/PR  245 days  pemetrexed/PD  0<56 days 
3 65/male  adenocarcinoma  unknown  erlotinib (5th-line)/SD  784 days  pemetrexed/SD  >105 days 
Present case  35/male  adenocarcinoma  wild-type  gefitinib (1st-line)/PR  223 days  gemcitabine + vinorelbine/PR <141 days 
EGFR-TKI = Epidermal growth factor receptor-tyrosine kinase inhibitor; PD = progressive disease; PR = partial response; SD = stable disease. 
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Fig. 1. CT of the chest at 2 months before PD (a), PD (b), 3 weeks after stopping gefitinib (c), and at 10 
days after restarting gefitinib (d). 
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